



February 14, 2007

The Honorable Henry Waxman  
Chairman, Committee on Oversight and Government Reform  
U.S. House of Representatives  
2204 Rayburn House Office Building  
Washington, D.C. 20515

**Re: Access to Life Saving Medicines Act of 2007**

Dear Congressman Waxman:

Momenta Pharmaceuticals, Inc. strongly applauds your leadership in introducing landmark, bipartisan legislation to bring safe, effective and affordable biogeneric pharmaceutical treatment choices to millions of Americans. The "Access to Life Saving Medicines Act of 2007" represents a timely and needed legislative effort to establish a science-based, abbreviated pathway for biogeneric and comparable products.

Momenta is a rapidly growing, Boston-based biotechnology company focused on the characterization and engineering of complex molecules. The company was established in 2001, built on a foundation characterization technology developed over a twelve year period at Massachusetts Institute of Technology. Momenta is applying its technology to product development in two areas: 1) creation of technology-enabled generic versions of sugar-based and other complex biologic products and 2) development of novel complex products based on our ability to characterize complex products, link their structures to biological function, and engineer improved versions.

Although we are a biotechnology company, we do believe the science exists to justify the establishment of an abbreviated pathway for FDA approvals of safe and effective comparable and biogeneric biologic drug candidates. We encourage Congress and the FDA to remain vigilant to the scientific issues involved in developing an abbreviated path. Without question, the details of this effort are of paramount importance, but our preliminary analysis of your legislation is that it meets the essential criteria of providing discretion to independent FDA scientists to make ultimate comparability and interchangeability judgments. If empowered by Congress to do so, we are confident that FDA will implement and operate such a pathway efficiently and effectively, produce consistent and timely reviews, and ensure the safety and efficacy of biogeneric and comparable drugs.

While we have not had time to evaluate all the provisions of your legislation, we wish to underscore our strong support for its introduction, enabling an abbreviated pathway for generic biologics. We stand ready to provide technical policy support throughout the upcoming legislative process. We look forward to working with you, Chairman Kennedy,

Letter to: The Honorable Henry Waxman  
February 14, 2007

Momenta Pharmaceuticals, Inc.  
Page 2 of 2

Chairman Dingell and other key Members of Congress on both sides of the aisle (as well as the FDA) to bring affordable biogeneric drugs to consumers.

Once again, we thank you for your leadership and foresight on this critically important opportunity addressing key pharmaceutical access, cost and safety issues.

Sincerely,



Craig A. Wheeler  
President and CEO, Momenta Pharmaceuticals, Inc.

cc. Chairman John Dingell, House Energy and Commerce Committee  
The Honorable Joe Barton, U.S. House of Representatives  
The Honorable Jo Ann Emerson, U.S. House of Representatives  
The Honorable Frank Pallone, U.S. House of Representatives

